Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19
On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…
-
-
University of Oxford scientists developed extremely rapid diagnostic test for Covid-19
On Oct. 15, 2020, scientists from the University of Oxford’s Department of Physics announced they had developed an…
-
FDA authorized phase 1 trial of ImmunityBioﾒs novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
-
Ionis antisense medicine evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
On Oct. 15, 2020, Ionis Pharmaceuticals announced that IONIS-PKK-LRx was being evaluated in an investigator-initiated Phase 2 clinical…
-
Tonix Pharmaceuticals enrolled first participant in PRECISION Study for COVID-19 vaccines and therapeutics
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
-
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
-
America’s Top Young Scientist of 2020: 14-year-old researched spike protein of SARS-CoV-2 virus
On Oct. 14, 2020, 3M and Discovery Education announced they had named 14-year-old Anika Chebrolu from Frisco, Texas,…
-
Tevogen Bio submitted IND for T cell treatment in COVID-19
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
-
Pfizer and BioNTech announced publication of phase 1 data on lead mRNA vaccine candidate against COVID-19
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
-
Brazilian Health Regulatory Agency authorized Sorrento’s phase 2 clinical trial of Abivertinib in COVID-19 patients
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
-
Global tuberculosis progress at risk during COVID-19 pandemic
On Oct. 14, 2020, the World Health Organization (WHO) announced that prior to the COVID-19 pandemic, many countries…
-
US DOD expanded collaboration with AstraZeneca to develop and manufacture an investigational mab to prevent COVID-19
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
-
Vaxart announced positive hamster challenge study data for its oral COVID-19 vaccine
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New…
-
DOD awarded $481 million to Cue Health to increase domestic production capacity of point-of-care testing
On Oct. 13, 2020, the Department of Defense (DOD), on behalf of the U.S. Department of Health and…
-
NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
-
COVID-19 vaccine with Dynavaxﾒs CpG 1018 adjuvant received Taiwan government subsidy with first dosage
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
-
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
-
Biotechnology | COVID-19 | NIH | Therapeutics
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
-
Apogenix advanced clinical development of CD95L inhibitor asunercept in European COVID-19 phase II trial
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
-
Cue received $481 million award to expand domestic production capacity of molecular, point-of-care COVID-19 tests
On Oct. 13, 2020, Cue Health announced a $481 Million award from the Department of Defense (DOD), on…
-
Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
-
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
-
Thermo Fisher Scientific expanded COVID-19 test portfolio with two new antibody tests
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
-
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
-
Rigel announced first patients enrolled in trial of fostamatinib in hospitalized COVID-19 patients in collaboration with Inova
On Oct. 9, 2020, Rigel Pharma announced enrollment of the first patients in a multicenter, Phase 2 trial…
-
OPKO Health’s BioReference Laboratories launched COVID-19 testing program for New York City schools
On Oct. 9, 2020, OPKO Health subsidiary BioReference Labs, New York City, the Department of Health, New York…
-
Pfizer Canada and BioNTech initiated rolling submission to Health Canada for SARS-CoV-2 vaccine candidate
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
-
Caladrius Biosciences opened study of CLBS119 to repair COVID-19-induced lung damage
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
-
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
NIH launched the Serological Sciences Network for COVID-19, announced grant and contract awardees
On Oct. 8, 2020, the National Cancer Institute (NCI) launched the Serological Sciences Network for COVID-19 (SeroNet), an…
